- Home
- ICG vs PLX Comparison
ICG vs PLX Comparison
Compare ICG & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICG
- PLX
- Stock Information
- Founded
- ICG 2017
- PLX 1993
- Country
- ICG China
- PLX United States
- Employees
- ICG N/A
- PLX N/A
- Industry
- ICG Semiconductors
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ICG Technology
- PLX Health Care
- Exchange
- ICG Nasdaq
- PLX Nasdaq
- Market Cap
- ICG 105.7M
- PLX 122.6M
- IPO Year
- ICG 2023
- PLX 1998
- Fundamental
- Price
- ICG $2.80
- PLX $1.43
- Analyst Decision
- ICG Strong Buy
- PLX Strong Buy
- Analyst Count
- ICG 2
- PLX 1
- Target Price
- ICG $9.25
- PLX $15.00
- AVG Volume (30 Days)
- ICG 346.9K
- PLX 1.3M
- Earning Date
- ICG 08-14-2025
- PLX 08-13-2025
- Dividend Yield
- ICG N/A
- PLX N/A
- EPS Growth
- ICG N/A
- PLX N/A
- EPS
- ICG 0.07
- PLX 0.05
- Revenue
- ICG $53,729,346.00
- PLX $59,764,000.00
- Revenue This Year
- ICG N/A
- PLX $65.02
- Revenue Next Year
- ICG $141.94
- PLX $57.34
- P/E Ratio
- ICG $36.80
- PLX $29.48
- Revenue Growth
- ICG 384.54
- PLX 0.18
- 52 Week Low
- ICG $1.19
- PLX $0.82
- 52 Week High
- ICG $12.04
- PLX $3.10
- Technical
- Relative Strength Index (RSI)
- ICG 66.82
- PLX 41.06
- Support Level
- ICG $1.75
- PLX $1.43
- Resistance Level
- ICG $2.79
- PLX $1.54
- Average True Range (ATR)
- ICG 0.38
- PLX 0.11
- MACD
- ICG 0.13
- PLX 0.02
- Stochastic Oscillator
- ICG 89.18
- PLX 28.57
About ICG Intchains Group Limited
Intchains Group Ltd provides integrated solutions consisting of high-performance ASIC chips and ancillary software and hardware for blockchain applications. Its ASIC chips are designed for several key blockchain algorithms including Blake2bsha3, sha512MD160, Cryptonight V4, Eaglesong, Blake2s and others. The company has built a proprietary technology platform named Xihe Platform, which allows the development of a wide range of ASIC chips with high efficiency and scalability. It designs its ASIC chips in-house, which enables it to leverage proprietary silicon data to deliver products reflecting the latest technological developments. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.